Association Between Continued Cannabis Use and Risk of Relapse in First-Episode Psychosis: A Quasi-Experimental Investigation Within an Observational Study.
paper
Cited
Public
Unavailable
- Authors
- Schoeler, Tabea; Petros, Natalia; Di Forti, Marta; Pingault, Jean-Baptiste; Klamerus, Ewa; Foglia, Enrico; Small, Amanda; Murray, Robin; Bhattacharyya, Sagnik
- Year
- 2016
- Journal
- JAMA psychiatry
- PMID
- 27680429
- DOI
- 10.1001/jamapsychiatry.2016.2427
IMPORTANCE: Cannabis use after first-episode psychosis is associated with poor outcomes, but the causal nature of this association is unclear. OBJECTIVE: To examine the precise nature of the association between continued cannabis use after the onset of psychosis and risk of relapse of psychosis. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study followed up for at least 2 years after the onset of psychosis 220 patients who presented to psychiatric services in South London, England, from April 12, 2002, to July 26, 2013, with first-episode psychosis. Longitudinal modeling (fixed-effects analysis, cross-lagged path analysis) was used to examine whether the association between changes in cannabis use and risk of relapse over time is the result of shared vulnerability between psychosis and cannabis use, psychosis increasing the risk of cannabis use (reverse causation), or a causal effect of cannabis use on psychosis relapse. INTERVENTIONS: Exposure to cannabis within the first and second years after onset of psychosis. MAIN OUTCOMES AND MEASURES: The main outcome measure was relapse of psychosis, defined as subsequent hospitalization for psychosis. Effect of cannabis use status in the first year (Ct1) and second year (Ct2) and pattern of cannabis use continuation in the first year and second year were modeled for risk of relapse in the first year (Rt1) and risk of relapse in the second year (Rt2) after psychosis onset. RESULTS: A total of 220 patients with first-episode psychosis were included in the analysis (mean [SD] age, 28.62 [8.58] years; age range, 18-65 years; 90 women [40.9%] and 130 men [59.1%]). Fixed-effects models that adjusted for time-variant (other illicit drug use, antipsychotic medication adherence) and time-invariant (eg, genetic or premorbid environment) unobserved confounders revealed that there was an increase in the odds of experiencing a relapse of psychosis during periods of cannabis use relative to periods of no use (odds ratio, 1.13; 95% CI, 1.03-1.24). Change in the pattern of continuation significantly increased the risk (odds ratio, 1.07; 95% CI, 1.02-1.13), suggesting a dose-dependent association. Cross-lagged analysis confirmed that this association reflected an effect of cannabis use on subsequent risk of relapse (Ct1βRt2: Ξ²β=β0.44, Pβ=β.04) rather than an effect of relapse on subsequent cannabis use (Rt1βCt2: Ξ²β=β-0.29, Pβ=β.59). CONCLUSIONS AND RELEVANCE: These results reveal a dose-dependent association between change in cannabis use and relapse of psychosis that is unlikely to be a result of self-medication or genetic and environmental confounding.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| A regulatory variant of CHRM3 is associated with cannabis-induced hallucinations in European Americans. | 2019 | 31740666 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Centering Individuals With Mental Illness as an At-Risk Group in the Era of Cannabis Legalization and Commercialization. | Hyatt AS | β | 2026 | β |
| Cannabis Use Cessation and the Risk of Psychotic Disorders: A Case-Control Analysis from the First Episode Case-Control EU-GEI WP2 Study: L'arrΓͺt de l'utilisation du cannabis et le risque de troubles psychotiques: Une analyse cas-tΓ©moins tirΓ©e de l'Γ©tude cas-tΓ©moins EU-GEI WP2 centrΓ©e sur les premiers Γ©pisodes psychotiques. | Bond BW et al. | β | 2025 | β |
| Changes in cannabis use post decriminalisation in mental health care users in South Africa. | Moshori R et al. | β | 2025 | β |
| Convergence of Cannabis and Psychosis on the Dopamine System. | Ahrens J et al. | β | 2025 | β |
| Correlates and trajectories of alcohol and cannabis misuse in the early phase of psychosis: Do we need substance specific interventions? | Spanevello C et al. | β | 2025 | β |
| Is treatment during a first hospitalization for an acute psychotic episode and after discharge associated with race or ethnicity? | Chow C et al. | β | 2025 | β |
| Modern perspectives on psychoses: dissociation, automatism, and temporality across exogenous and endogenous dimensions. | Ricci V et al. | β | 2025 | β |
| Recent cannabis use affects the association between baseline immune markers and long-term outcomes in psychosis. | Kreis I et al. | β | 2025 | β |
| Antipsychotic Use and Psychiatric Hospitalization in First-Episode Non-affective Psychosis and Cannabis Use Disorder: A Swedish Nationwide Cohort Study. | Denissoff A et al. | β | 2024 | β |
| Assessing rates and predictors of cannabis-associated psychotic symptoms across observational, experimental and medical research. | Schoeler T et al. | β | 2024 | β |
| Behind the heterogeneity in the long-term course of first-episode psychosis: Different psychotic symptom trajectories are associated with different patterns of cannabis and stimulant use. | Kreis I et al. | β | 2024 | β |
| Converging effects of cannabis and psychosis on the dopamine system: A longitudinal neuromelanin-sensitive MRI study in cannabis use disorder and first episode schizophrenia | Ahrens J et al. | β | 2024 | β |
| Neurotrophic Factors in Cannabis-induced Psychosis: An Update. | Ricci V et al. | β | 2024 | β |
| Perspectives of young adults diagnosed with early psychosis using coordinated specialty care in Texas on substance use and substance use interventions. | Myers NL et al. | β | 2024 | β |
| Predictors of relapse and engagement in care one year after ending services in an urban safety net coordinated specialty care program for first episode psychosis. | Hyatt A et al. | β | 2024 | β |
| Rethinking Mental Automatism: De ClΓ©rambault's Theory in the Age of Novel Psychoactive Drugs: Psychotropic Effects and Synthetic Psychosis. | Ricci V et al. | β | 2024 | β |
| Behavioral economic relationship between cannabis flower and concentrates: Evidence from simulated purchase tasks. | Panchalingam T et al. | β | 2023 | β |
| Cannabis use among patients presenting to the emergency department for psychosis: Associations with restraint use, medication administration, psychiatric hospitalization, and repeat visits. | Gouse BM et al. | β | 2023 | β |
| Cannabis Use and Symptomatic Relapse in First Episode Schizophrenia: Trigger or Consequence? Data From the OPTIMISE Study. | Levi L et al. | β | 2023 | β |
| Remission with or without comorbid substance use disorders in early psychosis: long-term outcome in integrated care (ACCESS III study). | RΓΌhl F et al. | β | 2023 | β |
| Stressful life events and relapse of psychosis: analysis of causal association in a 2-year prospective observational cohort of individuals with first-episode psychosis in the UK. | Bhattacharyya S et al. | β | 2023 | β |
| Aberrant hippocampal shape development in young adults with heavy cannabis use: Evidence from a longitudinal study. | Xu H et al. | β | 2022 | β |
| Cannabinoids, reward processing, and psychosis. | Gunasekera B et al. | β | 2022 | β |
| Cannabinoid treatments for anxiety: A systematic review and consideration of the impact of sleep disturbance. | Narayan AJ et al. | β | 2022 | β |
| Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis. | D'Souza DC et al. | β | 2022 | β |
| Differential sensitivity to the acute psychotomimetic effects of delta-9-tetrahydrocannabinol associated with its differential acute effects on glial function and cortisol. | Colizzi M et al. | β | 2022 | β |
| Examining the Use of Antidepressants for Adolescents with Depression/Anxiety Who Regularly Use Cannabis: A Narrative Review. | Hen-Shoval D et al. | β | 2022 | β |
| Impact of cannabis use and its cessation on the dosage and the efficacy of antipsychotic drugs in in- and outpatients with schizophrenia taking medication: A systematic review and meta-analysis. | Rault O et al. | β | 2022 | β |
| Schizophrenia: A Narrative Review of Etiopathogenetic, Diagnostic and Treatment Aspects. | Orsolini L et al. | β | 2022 | β |
| Timing of cannabis exposure relative to prodrome and psychosis onset in a community-based first episode psychosis sample. | Kline ER et al. | β | 2022 | β |
| Barriers and Facilitators That Influence Providers' Ability to Educate, Monitor, and Treat Substance Use in First-Episode Psychosis Programs Using the Theoretical Domains Framework. | Oluwoye O et al. | β | 2021 | β |
| Cannabidiol modulation of hippocampal glutamate in early psychosis. | O'Neill A et al. | β | 2021 | β |
| Cannabis-induced psychosis masquerading schizophrenia or vice-versa? A diagnostic dilemma. | Sharma R et al. | β | 2021 | β |
| Cannabis Use Among Patients With Psychotic Disorders. | Hirschtritt ME et al. | β | 2021 | β |
| Cannabis use disorder and dissociation: A report from a prospective first-episode psychosis study. | Ricci V et al. | β | 2021 | β |
| Disrupted parahippocampal and midbrain function underlie slower verbal learning in adolescent-onset regular cannabis use. | Blest-Hopley G et al. | β | 2021 | β |
| Early intervention services, patterns of prescription and rates of discontinuation of antipsychotic treatment in first-episode psychosis. | Catalan A et al. | β | 2021 | β |
| Endogenous antagonists of N-methyl-d-aspartate receptor in schizophrenia. | Jorratt P et al. | β | 2021 | β |
| Evaluation of THC-Related Neuropsychiatric Symptoms Among Adults Aged 50 Years and Older: A Systematic Review and Metaregression Analysis. | Velayudhan L et al. | β | 2021 | β |
| Eye movements in patients in early psychosis with and without a history of cannabis use. | Sami MB et al. | β | 2021 | β |
| Individualized prediction of 2-year risk of relapse as indexed by psychiatric hospitalization following psychosis onset: Model development in two first episode samples. | Bhattacharyya S et al. | β | 2021 | β |
| Psychosocial interventions for people with a first episode psychosis: between tradition and innovation. | Singh SP et al. | β | 2021 | β |
| Adolescent-onset heavy cannabis use associated with significantly reduced glial but not neuronal markers and glutamate levels in the hippocampus. | Blest-Hopley G et al. | β | 2020 | β |
| Association of cannabis with glutamatergic levels in patients with early psychosis: Evidence for altered volume striatal glutamate relationships in patients with a history of cannabis use in early psychosis. | Sami M et al. | β | 2020 | β |
| Cannabis use among U.S. adolescents in the era of marijuana legalization: a review of changing use patterns, comorbidity, and health correlates. | Hammond CJ et al. | β | 2020 | β |
| Characterising heterogeneity in the use of different cannabis products: latent class analysis with 55 000 people who use cannabis and associations with severity of cannabis dependence. | Craft S et al. | β | 2020 | β |
| Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis. | Colizzi M et al. | β | 2020 | β |
| The Changing Legal Landscape of Cannabis Use and Its Role in Youth-onset Psychosis. | Wright A et al. | β | 2020 | β |
| The influence of risk factors on the onset and outcome of psychosis: What we learned from the GAP study. | Murray RM et al. | β | 2020 | β |
| Trends in Cannabis Treatment Admissions in Adolescents/Young Adults: Analysis of TEDS-A 1992 to 2016. | Standeven LR et al. | β | 2020 | β |
| Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition. | Colizzi M et al. | β | 2020 | β |
| Antipsychotic treatment failure in patients with psychosis and co-morbid cannabis use: A systematic review. | Reid S et al. | β | 2019 | β |
| A regulatory variant of CHRM3 is associated with cannabis-induced hallucinations in European Americans. | Cheng Z et al. | β | 2019 | β |
| Cannabidiol as a potential treatment for psychosis. | Davies C et al. | β | 2019 | β |
| Descriptive Psychopathology of the Acute Effects of Intravenous Delta-9-Tetrahydrocannabinol Administration in Humans. | Colizzi M et al. | β | 2019 | β |
| Predictors of Hospitalization of Individuals With First-Episode Psychosis: Data From a 2-Year Follow-Up of the RAISE-ETP. | Robinson DG et al. | β | 2019 | β |
| Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders. | Sami MB et al. | β | 2018 | β |
| Developmental sensitivity to cannabis use patterns and risk for major depressive disorder in mid-life: findings from 40 years of follow-up. | Schoeler T et al. | β | 2018 | β |
| Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis: A Randomized Clinical Trial. | Bhattacharyya S et al. | β | 2018 | β |
| Longitudinal assessment of the effect of cannabis use on hospital readmission rates in early psychosis: A 6-year follow-up in an inpatient cohort. | Colizzi M et al. | β | 2018 | β |
| Modulation of acute effects of delta-9-tetrahydrocannabinol on psychotomimetic effects, cognition and brain function by previous cannabis exposure. | Colizzi M et al. | β | 2018 | β |
| The effects of cannabis use on salience attribution: a systematic review. | Wijayendran SB et al. | β | 2018 | β |
| The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis. | Hahn B | β | 2018 | β |
| The relative prevalence of schizophrenia among cannabis and cocaine users attending addiction services. | Libuy N et al. | β | 2018 | β |
| Cannabis use and adherence to antipsychotic medication: a systematic review and meta-analysis. | Foglia E et al. | β | 2017 | β |
| Does Cannabis Composition Matter? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition. | Colizzi M et al. | β | 2017 | β |
| Effect of continued cannabis use on medication adherence in the first two years following onset of psychosis. | Schoeler T et al. | β | 2017 | β |
| Improving outcomes of first-episode psychosis: an overview. | Fusar-Poli P et al. | β | 2017 | β |
| Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis. | Schoeler T et al. | β | 2017 | β |